10-102065523-G-GGCGGC
Position:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_024747.6(HPS6):c.60_64dup(p.Leu22ArgfsTer33) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000895 in 1,552,790 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000053 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000094 ( 0 hom. )
Consequence
HPS6
NM_024747.6 frameshift
NM_024747.6 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 2.96
Genes affected
HPS6 (HGNC:18817): (HPS6 biogenesis of lysosomal organelles complex 2 subunit 3) This intronless gene encodes a protein that may play a role in organelle biogenesis associated with melanosomes, platelet dense granules, and lysosomes. This protein interacts with Hermansky-Pudlak syndrome 5 protein. Mutations in this gene are associated with Hermansky-Pudlak syndrome type 6. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. There are 15 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 10-102065523-G-GGCGGC is Pathogenic according to our data. Variant chr10-102065523-G-GGCGGC is described in ClinVar as [Pathogenic]. Clinvar id is 1452276.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
HPS6 | NM_024747.6 | c.60_64dup | p.Leu22ArgfsTer33 | frameshift_variant | 1/1 | ENST00000299238.7 | NP_079023.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
HPS6 | ENST00000299238.7 | c.60_64dup | p.Leu22ArgfsTer33 | frameshift_variant | 1/1 | NM_024747.6 | ENSP00000299238 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000526 AC: 8AN: 152148Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
8
AN:
152148
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000192 AC: 3AN: 155942Hom.: 0 AF XY: 0.0000114 AC XY: 1AN XY: 88050
GnomAD3 exomes
AF:
AC:
3
AN:
155942
Hom.:
AF XY:
AC XY:
1
AN XY:
88050
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000935 AC: 131AN: 1400534Hom.: 0 Cov.: 31 AF XY: 0.0000878 AC XY: 61AN XY: 694778
GnomAD4 exome
AF:
AC:
131
AN:
1400534
Hom.:
Cov.:
31
AF XY:
AC XY:
61
AN XY:
694778
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000525 AC: 8AN: 152256Hom.: 0 Cov.: 33 AF XY: 0.0000403 AC XY: 3AN XY: 74450
GnomAD4 genome
AF:
AC:
8
AN:
152256
Hom.:
Cov.:
33
AF XY:
AC XY:
3
AN XY:
74450
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 24, 2023 | This sequence change creates a premature translational stop signal (p.Leu22Argfs*33) in the HPS6 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 754 amino acid(s) of the HPS6 protein. This variant is present in population databases (rs752399257, gnomAD 0.004%). This premature translational stop signal has been observed in individual(s) with Hermansky–Pudlak syndrome (PMID: 27593200, 29054114, 30990103). This variant is also known as c.64_65insGCGGC. ClinVar contains an entry for this variant (Variation ID: 1452276). This variant disrupts a region of the HPS6 protein in which other variant(s) (p.Q680*) have been determined to be pathogenic (PMID: 27225848). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 24, 2024 | Frameshift variant predicted to result in abnormal protein length as the last 754 amino acids are replaced with 32 different amino acids, and other similar variants have been reported in HGMD; This variant is associated with the following publications: (PMID: 30990103, 33878481, 27593200, 29054114, 27535533, 35644009, 38091959, 32725903) - |
HPS6-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 10, 2023 | The HPS6 c.60_64dup5 variant is predicted to result in a frameshift and premature protein termination (p.Leu22Argfs*33). This variant has been reported in the homozygous and compound heterozygous states in individuals with Hermansky-Pudlak syndrome 6 (reported as c.65_65insGCGGC in Wei et al 2016. PubMed ID: 27593200; Okamura et al. 2017. PubMed ID: 29054114; Bastida et al. 2019. PubMed ID: 30990103). This variant is reported in 0.0036% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/10-103825280-G-GGCGGC). Frameshift variants in HPS6 are expected to be pathogenic. Given the evidence, we interpret c.60_64dup (p.Leu22Argfs*33) as pathogenic. - |
Hermansky-Pudlak syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 27, 2023 | Variant summary: HPS6 c.60_64dupGCGGC (p.Leu22ArgfsX33) results in a frameshift and premature termination codon, predicted to cause a truncation of the encoded protein, a commonly known mechanism for disease. The variant allele was found at a frequency of 1.9e-05 in 155942 control chromosomes (gnomAD). c.60_64dupGCGGC has been reported in the literature as a biallelic genotype in multiple individuals affected with Hermansky-Pudlak Syndrome (e.g. Wei_2016, Okamura_2018, Bastida_2019). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One clinical diagnostic laboratory has submitted a clinical-significance assessment for this variant to ClinVar after 2014 and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at